As we are proposing MEK1/2 inhibitors to be a potential therapy for PwCF, we sought to determine if a MEK1/2 inhibitor compound can dampen inflammation in the CF mouse model without permitting excessive bacterial growth. Here, MAP2K1 is linked to cystic fibrosis.